|
|
|
|
|
|
Sponsored by: |
Pharmasset |
Information provided by: | Pharmasset |
ClinicalTrials.gov Identifier: | NCT00496158 |
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks, 72 weeks, and 96 weeks.
Condition | Intervention | Phase |
Chronic Hepatitis Hepatitis B |
Drug: Clevudine Drug: Adefovir |
Phase III |
MedlinePlus related topics: | Hepatitis Hepatitis B |
ChemIDplus related topics: | Hepatitis B Vaccines Adefovir dipivoxil Adefovir |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Safety/Efficacy Study |
Official Title: | A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: clinical.trials@pharmasset.com clinical.trials@pharmasset.com | clinical.trials@pharmasset.com |
Show 27 Study Locations |
Pharmasset |
Study Director: | M Michelle Berrey, MD, MPH | Pharmasset |
Study ID Numbers: | CI-PSI-5268-06-306 |
First Received: | July 2, 2007 |
Last Updated: | July 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00496158 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|